1228968-41-9

Upstream product

• 1007882-04-3 (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 994-89-8 tributylethynyltin 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1228968-40-8 C₂₃H₃₁N₃O₂Si 
• 1228968-40-8 C₂₃H₃₁N₃O₂Si 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 1007881-98-2 y 

Downstream Products

• 1250937-32-6 C₄₀H₄₆N₆O₄ 
• 1273592-24-7 C₃₈H₄₃FN₆O₄ 
• 1228968-46-4 2-((S)-pyrrolidin-2-yl)-5-(4-((2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)ethynyl)phenyl)-1H-imidazole 
• 1307304-55-7 (S)-tert-butyl 2-(5-(4-((2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)ethyl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1307304-56-8 2-((S)-pyrrolidin-2-yl)-5-(4-(2-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)ethyl)phenyl)-1H-imidazole 
• 1228964-80-4 C₅₄H₅₈N₈O₆ 
• 1228964-83-7 C₅₂H₅₀N₈O₄ 
• 1228964-86-0 C₄₄H₄₀N₆O₄ 
• 1228968-13-5 C₄₇H₅₀N₈O₆ 
• 1228968-16-8 C₄₇H₄₈N₈O₆ 
• 1242093-98-6 C₃₅H₄₁N₇O₄ 
• 1250937-40-6 C₄₀H₄₄N₆O₄ 
• 1228967-57-4 C₃₆H₄₂N₆O₄ 
• 1228968-45-3 C₃₉H₄₆N₆O₆S 

Relevant academic research and scientific papers

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors

NS5A inhibitors are a new class of direct-acting antiviral agents which display very potent anti-HCV activity in vitro and in humans. Rationally designed modifications to the central biphenyl linkage of a known NS5A series led to selection of several comp

INHIBITORS OF HCV NS5A

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

INHIBITORS OF HCV NS5A PROTEIN

Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

INHIBITORS OF HCV NS5A

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.